Risk assessment of esophageal adenocarcinoma using γ-H2AX assay.

Cancer Epidemiol Biomarkers Prev

Authors' Affiliations: Departments of Epidemiology and Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and Department of Pathology, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

Published: October 2013

Background: Mutagen-induced DNA damage as measured in peripheral blood lymphocytes (PBL) has been associated with increased risks of cancers. The formation of γ-H2AX is an early cellular response to DNA double-strand breaks (DSB). We hypothesize that higher level of radiation-induced γ-H2AX in PBLs may be associated with an increased risk of esophageal adenocarcinoma.

Methods: Laser scanning cytometer-based immunocytochemical method was used to measure baseline and irradiation-induced γ-H2AX levels in PBLs from 211 patients with esophageal adenocarcinoma and 211 healthy controls. The ratio of induced γ-H2AX level to baseline level was used to evaluate individual susceptibility to DSBs. Relative risks for esophageal adenocarcinoma associated with γ-H2AX were assessed by multivariable logistic regression analysis.

Results: Radiation-induced γ-H2AX level and the γ-H2AX ratio were significantly higher in cases than in controls. Dichotomized at the median in controls, a significantly increased risk for esophageal adenocarcinoma was observed in association with high γ-H2AX ratio [OR = 2.94; 95% confidence interval (CI), 1.83-4.72]. Quartile analyses showed significant dose-response associations between higher γ-H2AX ratio and increased risk of esophageal adenocarcinoma (Ptrend, 1.64E-06). In addition, joint effect between γ-H2AX ratio and smoking was observed: smokers who had high γ-H2AX ratio exhibited the highest risk of esophageal adenocarcinoma (OR = 5.53; 95% CI, 2.71-11.25) compared with never smokers with low γ-H2AX ratio.

Conclusion: Radiation-induced DNA damage assessed by γ-H2AX ratio is associated with an increased risk of esophageal adenocarcinoma.

Impact: γ-H2AX assay is a new and robust method to measure DSB damage in PBLs, which can be used to assess mutagen sensitivity and esophageal adenocarcinoma risk.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824382PMC
http://dx.doi.org/10.1158/1055-9965.EPI-13-0485DOI Listing

Publication Analysis

Top Keywords

esophageal adenocarcinoma
28
γ-h2ax ratio
24
risk esophageal
20
increased risk
16
γ-h2ax
15
associated increased
12
esophageal
9
γ-h2ax assay
8
dna damage
8
radiation-induced γ-h2ax
8

Similar Publications

Purpose Of Review: This review addresses the current treatment paradigm and new advancements in the management of microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) esophagogastric cancer (EGC).

Recent Findings: While chemotherapy and surgery remain the cornerstone of EGC treatment, MSI-H/dMMR tumors harbor high tumor mutational burden and represent a subset of patients who benefit from immune checkpoint inhibitors (ICI). ICI has been incorporated in the front line setting with and without chemotherapy for advanced disease.

View Article and Find Full Text PDF

Background: Barrett's esophagus (BE) is a precancerous condition often associated with esophageal adenocarcinoma, influenced by both genetic and environmental factors. However, there is controversy regarding the causal relationship between cerebral cortical structures and BE, with recent studies suggesting a potential neurobiological component to its multifactorial etiology. This study aims to clarify this relationship by utilizing Mendelian randomization (MR) analysis to investigate the potential causal effects of cortical structure variations on BE risk.

View Article and Find Full Text PDF

Current landscape of immunotherapy in esophageal cancer: a literature review.

J Thorac Dis

December 2024

Department of Surgery and Thoracic Surgery, Ascension Providence Hospital, Michigan State University College of Human Medicine, Southfield, MI, USA.

Background And Objective: Esophageal cancer has witnessed a significant shift in its epidemiology within the United States. Adenocarcinoma of the esophagus is now the fastest-growing solid malignancy, surpassing esophageal squamous cell carcinoma (ESCC) in frequency. There has been a concentrated effort to establish new therapies for dealing with this malignancy including immunotherapy in conjunction with surgery and radiotherapy.

View Article and Find Full Text PDF

LncRNA HOXA10-AS as a novel biomarker and therapeutic target in human cancers.

Front Mol Biosci

January 2025

Department of Immunology, School of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, Shandong, China.

Long non-coding RNAs (lncRNAs) are crucial regulatory molecules that participate in numerous cellular development processes, and they have gathered much interest recently. HOXA10 antisense RNA (HOXA10-AS, also known as HOXA-AS4) is a novel lncRNA that was identified to be dysregulated in some prevalent malignancies. In this review, the clinical significance of HOXA10-AS for the prognosis of various cancers is analyzed.

View Article and Find Full Text PDF

[Status and prospect of esophageal cancer screening].

Zhonghua Zhong Liu Za Zhi

January 2025

Cancer Registry Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, China.

Esophageal cancer is one of the global public health problems, which is a serious threat to life and health. Screening is not only an important main measures to reduce the incidence and mortality of esophageal cancer, but also an effective strategy for early prevention and early treatment. There are significant differences in the screening status of esophageal adenocarcinoma and esophageal squamous cell carcinoma cancer between China and abroad.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!